NSCLC

Question 1

CHEMOTHERAPY REGIMENS FOR NEOADJUVANT AND ADJUVANT THERAPY

Answer 1

• Cisplatin 50 mg/m2 days 1 and 8; vinorelbine 25 mg/m2 days 1, 8, 15, 22, every 28 days for 4 cycles
• Cisplatin 100 mg/m2 day 1; 
vinorelbine 30 mg/m2 days 1, 8, 15, 22, 
every 28 days for 4 cycles
• Cisplatin 75–80 mg/m2 day 1; 
vinorelbine 25–30 mg/m2 days 1 + 8, 
every 21 days for 4 cycles 
• Cisplatin 100 mg/m2 day 1; 
etoposide 100 mg/m2 days 1–3, 
every 28 days for 4 cycles
• Cisplatin 75 mg/m2 day 1; 
gemcitabine 1250 mg/m2 days 1, 8, 
every 21 days for 4 cycles
• Cisplatin 75 mg/m2 day 1; 
docetaxel 75 mg/m2 day 1 
every 21 days for 4 cycles 
• Cisplatin 75 mg/m2 day 1, 
pemetrexed 500 mg/m2 day 1 for nonsquamous every 21 days for 4 cycles

Chemotherapy Regimens for Patients with Comorbidities or Patients Not Able to Tolerate Cisplatin
Paclitaxel 200 mg/m2 day 1, carboplatin AUC 6 day 1, every 21 days

Question 2

CHEMOTHERAPY REGIMENS USED WITH RADIATION THERAPY

Concurrent Chemotherapy/RT Regimens

Answer 2

• Cisplatin 50 mg/m2 on days 1, 8, 29,36; 
etoposide 50 mg/m2 days 1–5, 29–33; 
concurrent thoracic RT 
• Cisplatin 100 mg/m2 days 1 and 29; 
vinblastine 5 mg/m2/weekly x 5; 
concurrent thoracic RT 
• Carboplatin AUC 5 on day 1, 
pemetrexed 500 mg/m2 on day 1 every 21 days for 4 cycles; 

concurrent thoracic RT(nonsquamous)
• Cisplatin 75 mg/m2 on day 1,
pemetrexed 500 mg/m2 on day 1 every 21 days for 3 cycles;
concurrent thoracic RTd,e (nonsquamous) ± additional 4 cycles of pemetrexed 500 mg/m2
• Paclitaxel 45–50 mg/m2 weekly;
carboplatin AUC 2, concurrent thoracic RT ± additional 2 cycles of paclitaxel 200 mg/m2 and carboplatin AUC 6

Sequential Chemotherapy/RT Regimens (Adjuvant) • Cisplatin 100 mg/m2 on days 1 and 29; vinblastine 5 mg/m2/wkly on days 1, 8, 15, 22,29; followed by RT
• Paclitaxel 200 mg/m2 over 3 hours on day 1; carboplatin AUC 6 over 60 minutes on day 1 every 3 weeks for 2 cycles followed by thoracic RT

Question 3

SYSTEMIC THERAPY FOR ADVANCED OR METASTATIC DISEASE (2 of 4)

First-line Systemic Therapy Options Adenocarcinoma, Large Cell, NSCLC NOS (PS 0-1)

Answer 3

Bevacizumab/carboplatin/paclitaxel (category 1) 
• Bevacizumab/carboplatin/pemetrexed
• Bevacizumab/cisplatin/pemetrexed
• Carboplatin/albumin-bound paclitaxel(category 1)
• Carboplatin/docetaxel (category 1)
• Carboplatin/etoposide (category 1)
• Carboplatin/gemcitabine (category 1)
• Carboplatin/paclitaxel (category 1)
• Carboplatin/pemetrexed (category 1)
• Cisplatin/docetaxel (category 1)
• Cisplatin/etoposide (category 1)
• Cisplatin/gemcitabine (category 1)
• Cisplatin/paclitaxel (category 1)
• Cisplatin/pemetrexed (category 1)
• Gemcitabine/docetaxel (category 1)
• Gemcitabine/vinorelbine (category 1)

Question 4

SYSTEMIC THERAPY FOR ADVANCED OR METASTATIC DISEASE (2 of 4)
First-line Systemic Therapy Options
Adenocarcinoma, Large Cell, NSCLC NOS (PS 2)

Answer 4

• Albumin-bound paclitaxel
• Carboplatin/albumin-bound paclitaxel
• Carboplatin/docetaxel
• Carboplatin/etoposide
• Carboplatin/gemcitabine
• Carboplatin/paclitaxel
• Carboplatin/pemetrexed
• Docetaxel
• Gemcitabine
• Gemcitabine/docetaxel
• Gemcitabine/vinorelbine
• Paclitaxel
• Pemetrexed

Question 5

SYSTEMIC THERAPY FOR ADVANCED OR METASTATIC DISEASE (2 of 4)
First-line Systemic Therapy Options
Squamous Cell Carcinoma (PS 0-1)

Answer 5

• Carboplatin/albumin-bound paclitaxel (category 1)
• Carboplatin/docetaxel (category 1)
• Carboplatin/gemcitabine (category 1)
• Carboplatin/paclitaxel (category 1)
• Cisplatin/docetaxel (category 1)
• Cisplatin/etoposide (category 1)
• Cisplatin/gemcitabine (category 1)
• Cisplatin/paclitaxel (category 1)
• Gemcitabine/docetaxel (category 1)
• Gemcitabine/vinorelbine (category 1)

Question 6

SYSTEMIC THERAPY FOR ADVANCED OR METASTATIC DISEASE (2 of 4)
First-line Systemic Therapy Options
Squamous Cell Carcinoma (PS 2)

Answer 6

• Albumin-bound paclitaxel
• Carboplatin/albumin-bound paclitaxel
• Carboplatin/docetaxel
• Carboplatin/etoposide
• Carboplatin/gemcitabine
• Carboplatin/paclitaxel
• Docetaxel
• Gemcitabine
• Gemcitabine/docetaxel
• Gemcitabine/vinorelbine
• Paclitaxel